Rankings
▼
Calendar
AMPH Q4 2025 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
AMPH
Amphastar Pharmaceuticals, Inc.
$894M
Q4 2025 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$183M
-1.8% YoY
Gross Profit
$86M
46.8% margin
Operating Income
$36M
19.4% margin
Net Income
$24M
13.3% margin
EPS (Diluted)
$0.51
QoQ Revenue Growth
-4.6%
Cash Flow
Operating Cash Flow
-$123M
Free Cash Flow
-$97M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$1.6B
Total Liabilities
$840M
Stockholders' Equity
$789M
Cash & Equivalents
$170M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$183M
$187M
-1.8%
Gross Profit
$86M
$87M
-1.1%
Operating Income
$36M
$45M
-21.1%
Net Income
$24M
$38M
-35.7%
Revenue Segments
Epinephrine
$36M
100%
Geographic Segments
UNITED STATES
$172M
100%
← FY 2025
All Quarters